- Company
- The government restricted the exemption to antibacterials
- by Eo, Yun-Ho Oct 19, 2020 06:19am
- The government restricted the exemption from economic evaluation to only antibacterial agents. There is great backlash. The HIRA confirmed the amendment to the regulations regarding evaluation standards and procedures, such as whether or not drugs are eligible for medical care benefits, by publicizing internal regulations on the 8th. The r
- Company
- Issues to look into when pricing drug by each indication
- by Eo, Yun-Ho Oct 17, 2020 06:37am
- Amending a regulatory system is not a simple work. Moreover, introducing the indication-specific drug pricing would have to entirely change the premise of the National Health Insurance (NHI) system that grants ‘unified insured pricing on a single drug.’ Regardless of the final result, the government would need to have detailed discussions
- Company
- Different use different price for same substance drugs?
- by Eo, Yun-Ho Oct 15, 2020 06:06am
- One says “Why should drugs cost the same when their effects, target patient sizes and values are different?” Another argues, “Why should I pay more for a drug that shares a common substance with other drugs?” In some way, both of those arguments make sense. And it is considered a conventional conflict of interest between a seller and
- Company
- The patent dispute over Otezla is expected to be fierce
- by Kim, Jin-Gu Oct 15, 2020 06:06am
- The patent dispute over the psoriasis treatment 'Otezla (Apremilast)' is expected to be fierce. In 15 days, eight companies had a patent challenge. Considering the fact that this treatment has not yet been officially released in Korea, it is evaluated that it is receiving great attention from domestic companies. According to the pharmac
- Company
- SK Biopharm, to export technology for XCOPRI to Japan
- by An, Kyung-Jin Oct 15, 2020 06:05am
- SK Biopharm announced on the 13th that it has signed a technology export contract for the development and commercialization of XCOPRI (Cenobamate), a new epilepsy drug, in Japan with Ono Pharma. With this contract, SK Biopharm secured ¥5 billion (approximately &8361;54.5 billion) in a down payment without obligation to return it. It
- Company
- Law firms hire drug industry personnel to expand clients
- by Eo, Yun-Ho Oct 14, 2020 06:23am
- Law firms in South Korea are busy scouting pharmaceutical industry specialists to attract pharmaceutical company clients. The related industry sources reported law firms like Kim & Chang, Lee & Ko, Yulchon and Shin & Kim have recruited external experts for their healthcare teams for the last month. Shin & Kim has welcomed a former di
- Company
- Daewoong's subsidiaries are all expected to turn profits
- by Oct 12, 2020 06:16am
- Daewoong's eight overseas subsidiaries are expected to make a profit this year. In the first half of this year, seven have already made a surplus. It has been about 10 years since the global organization has been in full swing. Daewoong has been the most actively seeking overseas expansion among domestic pharmaceutical companies. Starting wit
- Company
- Pfizer seeks for approval on NSCLC drug ‘lorlatinib’
- by Kim, Jin-Gu Oct 12, 2020 06:15am
- Pfizer has taken a first step to launch a non-small cell lung cancer (NSCLC) treatment ‘lorlatinib’ in the South Korean market. According to a pharmaceutical industry source on Oct. 7, Pfizer Pharmaceutical Korea has recently submitted an application to the Ministry of Food and Drug Safety (MFDS) to request an item approval on lorlatin
- Company
- Roche Diagnosis provides COVID-19 customized diagnostic test
- by Oct 8, 2020 06:23am
- Roche Diagnostics Korea, which celebrates its 30th anniversary, has promised to provide rapid diagnostic tests in the pendemic. On the 6th, Roche Diagnostics Korea held an online press conference to commemorate the 30th anniversary of its founding, highlighting the value of diagnosis and the role of Roche Group in the situation of COVID-19.
- Company
- MSD on final stretch with Keytruda coverage expansion
- by Eo, Yun-Ho Oct 7, 2020 06:09am
- MSD Korea made the last move for the Keytruda coverage expansion. Now it is back to the government’s turn to make the decision. Related industry sources confirmed, MSD has submitted the final financial expense sharing plan to Health Insurance Review and Assessment Service (HIRA) after revising the detailed strategies regarding the reim
